Survivorship – Kidney Cancer

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

ELIGIBILITY

Kidney cancer after completion of treatment and NED (Patients with suspected or confirmed Von Hippel-Lindau disease are excluded)

CONCURRENT COMPONENTS OF VISIT

Low Risk\(^2\) and Intermediate Risk\(^3\)

Follow-up visit at 48\(^4\) months and another at 60 months:
- History & physical exam
- BUN, creatinine, alkaline phosphatase, CBC with differential, ALT, AST, LDH, and total bilirubin
- Chest x-ray
- CT or MRI abdomen with contrast or ultrasound abdomen every 2-3 years

Follow-up visit between 72–84 months and another between 96–120 months:
- History & physical exam
- BUN, creatinine, alkaline phosphatase, CBC with differential, ALT, AST, LDH, and total bilirubin
- Chest x-ray
- CT or MRI abdomen with contrast or ultrasound abdomen every 2-3 years

High Risk\(^5\) and Very High Risk\(^6\)

Follow-up visit at 84\(^7\) months and another between 96–120 months:
- History & physical exam
- BUN, creatinine, alkaline phosphatase, CBC with differential, ALT, AST, LDH, and total bilirubin
- Chest x-ray
- CT chest with contrast (chest x-ray may be utilized instead)
- CT or MRI of abdomen with contrast or ultrasound abdomen every 2 years

MONITORING FOR LATE EFFECTS

RISK REDUCTION/EARLY DETECTION

PSYCHOSOCIAL FUNCTIONING

DISPOSITION

New primary or recurrent disease?

Yes

Return to primary treating physician

No

Continue survivorship monitoring

\(^1\) Von Hippel-Lindau disease (VHL) is a hereditary condition associated with tumors arising in multiple organs

\(^2\) Low Risk (LR): pT1 and Grade 1/2

\(^3\) Intermediate Risk (IR): pT1 and Grade 3/4 or pT2 any Grade

\(^4\) Primary urology team will order the needed tests for the initial survivorship visit (at 48 months) at the 24 months visit with primary for LR and at the 36 months visit for IR

\(^5\) High Risk (HR): pT3 any Grade

\(^6\) Very High Risk (VHR): pT4 or pN1, or sarcomatoid/rhabdoid dedifferentiation or macroscopic positive margin

\(^7\) Primary urology team will order the needed tests for the initial survivorship visit (at 84 months) at the 60 months visit with primary for HR and VHR

NED = no evidence of disease

Page 2

Approved by the Executive Committee of the Medical Staff on 04/19/2022

Department of Clinical Effectiveness V8

Copyright 2022 The University of Texas MD Anderson Cancer Center
Survivorship – Kidney Cancer

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

ELIGIBILITY

- Kidney cancer after completion of treatment and NED (Patients with suspected or confirmed Von Hippel-Lindau disease are excluded)

CONCURRENT COMPONENTS OF VISIT

- MONITORING FOR LATE EFFECTS
  - Assess for renal insufficiency

- RISK REDUCTION/EARLY DETECTION
  - Patient education, counseling, and screening:
    - Lifestyle risk assessment
    - Cancer screening
    - HPV vaccination as clinically indicated (see HPV Vaccination algorithm)
    - Screening for Hepatitis B and C as clinically indicated (see Hepatitis B Virus (HBV) Screening and Management algorithm)
    - Consider cardiovascular risk reduction
    - Vaccinations as appropriate

- PSYCHOCO SOCIAL FUNCTIONING
  - Assess for:
    - Distress management (see Distress Screening and Psychosocial Management algorithm)
    - Body image
    - Financial stressors
    - Social support

DISPOSITION

- Refer or consult as indicated

---

1. Von Hippel-Lindau disease (VHL) is a hereditary condition associated with tumors arising in multiple organs.
2. Consider nephrology referral or consult for eGFR < 60 mL/min/1.73m² or abnormal urine analysis result.
3. Includes breast, cervical (if appropriate), colorectal, liver, lung, pancreatic, prostate, and skin cancer screening.
4. Consider use of Vanderbilt’s ABCDE’s approach to cardiovascular health.
5. Based on Centers for Disease Control and Prevention (CDC) guidelines.

References:
- "Physical Activity, Nutrition, and Tobacco Cessation algorithms"
- "Hepatitis B Virus (HBV) Screening and Management algorithm"
- "Distress Screening and Psychosocial Management algorithm"
Survivorship – Kidney Cancer

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS


Continued on next page
SUGGESTED READINGS - continued


This survivorship algorithm is based majority expert opinion of the Genitourinary Survivorship workgroup at The University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

**Core Development Team Lead**
Jose A. Karam, MD (Urology)

**Workgroup Members**
Katherine Gilmore, BA, MPH (Cancer Survivorship)
William Graber, MD (Urology)
Eric Jonasch, MD (Genitourinary Medical Oncology)
Thoa Kazantsev, MSN, RN, OCN*
Deborah A. Kuban, MD (Radiation Oncology Department)
Surena Matin, MD (Urology)
William E. Osai, MSN, RN, FNP (Genitourinary Medical Oncology)
Raghu Vikram, MD (Abdominal Imaging Department)

*Clinical Effectiveness Development Team